| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d9c8769333a927911f9d7edcc10ab8a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0226
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0667
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 |
| filingDate |
2019-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_613cfe71f4760235397eacbf6b99de79 |
| publicationDate |
2020-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020087626-A1 |
| titleOfInvention |
Wnt-activated adipose-derived stem cell apparatuses, methods and systems |
| abstract |
The WNT-ACTIVATED ADIPOSE-DERIVED STEM CELL APPARATUSES, METHODS AND SYSTEMS (hereinafter “WAADSC”) disclosed herein in various embodiments provide for production of an isolated and enriched population of mesenchymal stem cells that have an active Wnt signaling demonstrated by the elevated expression of Lrg5 marker and/or Nestin in more than 50% of the population. Such an autologous cell population may, in embodiments, be injected into cerebral ventricles of patients with neurodegenerative diseases to yield therapeutic results, such as halting the progression of certain conditions and/or ameliorating specific symptoms thereof |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2770364-C1 |
| priorityDate |
2018-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |